

A practical guide for providers on helping patients locate Benazepril, navigate availability challenges, and maintain uninterrupted blood pressure treatment.
When patients call your office saying they can't fill their Benazepril prescription, it creates a cascade of problems: missed doses, uncontrolled blood pressure, anxious patients, and additional work for your staff. While Benazepril is not currently in a national shortage, localized availability issues are common enough that having a plan in place can save your practice time and improve patient outcomes.
This guide provides a step-by-step approach to helping your patients maintain access to Benazepril or transition smoothly to an equivalent alternative.
Benazepril Hydrochloride (formerly marketed as Lotensin) is a generic ACE inhibitor available in 5 mg, 10 mg, 20 mg, and 40 mg oral tablets. As of 2026:
The primary challenge is distribution-level disruption: pharmacies on single-distributor contracts may face temporary allocation limits, while manufacturers continue producing adequate quantities at the national level.
Understanding the root causes helps you advise patients more effectively:
The three major U.S. drug distributors (McKesson, Cardinal Health, AmerisourceBergen) occasionally limit pharmacy orders for specific products. Chain pharmacies with exclusive distributor contracts are most vulnerable. Independent pharmacies with multi-distributor relationships are better positioned to source alternative stock.
Pharmacies carry inventory based on their patient population's prescribing patterns. A pharmacy that fills relatively few Benazepril prescriptions may not stock it in depth, requiring special orders that take one to two business days.
A pharmacy may have some Benazepril strengths available but not others. The 5 mg and 40 mg tablets, which are less commonly prescribed than the 10 mg and 20 mg, may be harder to find at any given pharmacy.
Rural pharmacies and those in underserved areas may have less consistent access to the full range of generic medications. Urban areas with more pharmacy options provide patients more flexibility.
Medfinder for Providers allows your staff to quickly check which pharmacies near your patient have Benazepril in stock. Consider integrating this into your workflow:
When chain pharmacies are out of stock, independent pharmacies are often the solution. Maintain a list of reliable independent pharmacies in your area. These pharmacies:
Small prescribing adjustments can reduce the chance of stock-outs:
For patients who truly cannot access Benazepril, having pre-established switching protocols reduces delays:
ACE Inhibitor Alternatives:
ARB Alternatives (for ACE inhibitor-intolerant patients):
After switching, monitor blood pressure within 1-2 weeks and check serum creatinine and potassium, particularly in patients with CKD, diabetes, or heart failure.
Give patients the tools and knowledge to navigate availability issues independently:
For a comprehensive comparison of Benazepril alternatives, see our article on alternatives to Benazepril. Key points for clinical decision-making:
Benazepril availability issues are a manageable challenge that doesn't require clinical compromise. By leveraging tools like Medfinder for Providers, maintaining switching protocols, and empowering patients with practical resources, your practice can ensure uninterrupted hypertension management.
The goal is straightforward: no patient should miss doses of their blood pressure medication because of a pharmacy stock-out. With the right systems in place, that's an achievable standard.
Related reading:
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.